Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Threshold initiates phase I/II pancreatic cancer trial
Phase I of the Glufosfamide/gemcitabine study will evaluate various doses of Glufosfamide in combination with the standard dose of gemcitabine in patients with any kind of advanced solid
Phase I of the Glufosfamide/gemcitabine study will evaluate various doses of Glufosfamide in combination with the standard dose of gemcitabine in patients with any kind of advanced solid
ACT 1 measured the safety and efficacy of intravenous RSD1235 in 416 patients with atrial arrhythmia. The primary endpoint in ACT 1 was conversion of recent-onset AF to
The new formulation of Invirase (saquinavir mesylate), which was approved under a six-month priority FDA review, will reduce pill count for each dose by more than half (from
If approved, the new product would be the first complete highly active antiretroviral therapy (HAART) treatment regimen for HIV available in a fixed-dose combination taken once daily. The
The National Institute of Allergy and Infectious Diseases (NIAID)/ National Institutes of Health (NIH) award is for $993,771 and will be used to screen the genomes of variola
The trial concerns an agreement made between the two companies, originally entered into in 1993 and replaced in 1995, under which Cambridge Antibody Technology (CAT) licensed Abbott to
Genaissance said the findings may apply to other drugs that also affect white blood cell counts. “In light of recent drug withdrawals and labeling restrictions due to rare
MGCD0103 is a rationally designed isotypic selective small molecule inhibitor of histone deacetylase (HDAC). The second hematologic cancer trial is scheduled to be initiated in early 2005. Both
The phase I clinical trial is a randomized, double-blind, placebo-controlled evaluation in healthy volunteers of the safety and pharmacokinetics of single rising oral doses of the drug candidate,
The interim analysis indicated that AIC was safely administered and systemic adverse reactions were similar between the AIC and control arms. Dynavax intends to complete the two-year clinical